Antigen Advancements: Unveiling the Generation of Subunit Vaccines

Global subunit vaccine market is anticipated to grow at a significant CAGR of 10.9% during the forecast period (2024-2031). The market growth is primarily driven by the rising demand for immunization better safety vaccines and the growing prevalence of infectious diseases. In developed and developing countries, strong government support for vaccine development is contributing to market growth. Additionally, various initiatives by global health organizations and biopharmaceutical corporations are driving market growth during the forecast period.

Browse the full report description of “Subunit Vaccine Market Size, Share & Trends Analysis Report by Product Type (Protein Antigen, and Polysaccharide Antigen), by Production Type (Denaturing of Proteins, and Genetic Engineering), by Immune Responses Type (Antigen-Presenting Cells (APCs), Cell-Mediated Immunity, Cytokines, Mucosal, and Others), and by Disease (Infectious Disease, Diphtheria, Tetanus and Pertussis (DTP), HPV, Measles, Mumps and Rubella (MMR), and Others) Forecast Period (2024-2031)” at https://www.omrglobal.com/industry-reports/subunit-vaccine-market

Recent Advancements in the Global Subunit Vaccine Market

• In April 2024, Bharat Biotech and Bilthoven Biologicals B.V. entered into a collaboration to produce and supply oral polio vaccines.

• In August 2023, Pfizer Inc. (US) received approval from the US FDA (Food and Drug Administration) for ABRYSVO, a bivalent RSV prefusion F (RSVpreF) vaccine to prevent LRTD (Lower Respiratory Tract Disease) and severe LRTD caused by RSV (Respiratory syncytial (sin-SISH-ul) virus) in infants from birth up to six months of age by active immunization of pregnant individuals at 32 through 36 weeks gestational age.

• In January 2023, Bharat Biotech launched Incovacc World’s first intranasal COVID vaccine for Primary series and Heterologous booster.

• In May 2023, GSK plc received US FDA approval for Arexvy (RSV, adjuvanted) for the prevention of Lower Respiratory Tract Disease (LRTD) caused by RSV in individuals 60 years of age and older.

Market Coverage

• The market number available for – 2023-2031

• Base year- 2023

• Forecast period- 2024-2031

• Segment Covered-

o By Product Type

o By Production Type

o By Immune Responses Type

o By Disease

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape- GlaxoSmithKline PLC, Merck & Co. Inc., Pfizer, Inc., Reber Genetics, and Sanofi S.A. among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Subunit Vaccine Market Report Segment

By Product Type

• Protein Antigen
• Polysaccharide Antigen

By Production Type

• Denaturing of Proteins
• Genetic Engineering

By Immune Response Type

• Antigen-Presenting Cells (APCs)
• Cell-Mediated Immunity
• Cytokines 
• Mucosal 
• Others (Innate Immune Response)

By Disease

• Infectious Disease
• Diphtheria
• Tetanus & Pertussis (DTP)
• HPV (Human Papillomavirus)
• Measles
• Mumps & Rubella (MMR) 
• Others (Rotavirus)

Global Subunit Vaccine Market Report Segment by Region

North America

• United States

• Canada 

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/subunit-vaccine-market